FoCUS has identified an issue that may be a barrier to timely patient access to durable therapies. The advent of expensive, one-time durable therapies will require changes in private payer benefit packages in order to avoid onerous financial burdens on patients and their families, which could result in delays due to state insurance review processes
Share this Post